Affimed NV Logo Image

Affimed NV

Affimed NV has reached its limit for report views.

Please check back to see if Affimed NV has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2015 Annual Report

Affimed NV

Affimed NV does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



About Affimed NV

11-50 Employees
Based in Heidelberg, Germany

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.

Ticker:
AFMD
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol